Your browser doesn't support javascript.
loading
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.
Sanchez-Vega, Francisco; Hechtman, Jaclyn F; Castel, Pau; Ku, Geoffrey Y; Tuvy, Yaelle; Won, Helen; Fong, Christopher J; Bouvier, Nancy; Nanjangud, Gouri J; Soong, Joanne; Vakiani, Efsevia; Schattner, Mark; Kelsen, David P; Lefkowitz, Robert A; Brown, Karen; Lacouture, Mario E; Capanu, Marinela; Mattar, Marissa; Qeriqi, Besnik; Cecchi, Fabiola; Tian, Yuan; Hembrough, Todd; Nagy, Rebecca J; Lanman, Richard B; Larson, Steven M; Pandit-Taskar, Neeta; Schöder, Heiko; Iacobuzio-Donahue, Christine A; Ilson, David H; Weber, Wolfgang A; Berger, Michael F; de Stanchina, Elisa; Taylor, Barry S; Lewis, Jason S; Solit, David B; Carrasquillo, Jorge A; Scaltriti, Maurizio; Schultz, Nikolaus; Janjigian, Yelena Y.
Afiliación
  • Sanchez-Vega F; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hechtman JF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Castel P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ku GY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Tuvy Y; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Won H; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Fong CJ; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bouvier N; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Nanjangud GJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Soong J; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Vakiani E; Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schattner M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kelsen DP; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Lefkowitz RA; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Brown K; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Lacouture ME; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Capanu M; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mattar M; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Qeriqi B; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Cecchi F; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Tian Y; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hembrough T; NantOmics, Rockville, Maryland.
  • Nagy RJ; NantOmics, Rockville, Maryland.
  • Lanman RB; NantOmics, Rockville, Maryland.
  • Larson SM; Guardant Health, Inc., Redwood City, California.
  • Pandit-Taskar N; Guardant Health, Inc., Redwood City, California.
  • Schöder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Iacobuzio-Donahue CA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ilson DH; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Weber WA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Berger MF; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • de Stanchina E; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Taylor BS; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Lewis JS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Solit DB; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Carrasquillo JA; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Scaltriti M; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schultz N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Janjigian YY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Discov ; 9(2): 199-209, 2019 02.
Article en En | MEDLINE | ID: mdl-30463996
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Amplificación de Genes / Receptor ErbB-2 / Proteínas Proto-Oncogénicas c-met Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Amplificación de Genes / Receptor ErbB-2 / Proteínas Proto-Oncogénicas c-met Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2019 Tipo del documento: Article